Title |
Progression in smoldering Waldenström macroglobulinemia: long-term results
|
---|---|
Published in |
Blood, March 2012
|
DOI | 10.1182/blood-2011-10-384768 |
Pubmed ID | |
Authors |
Robert A. Kyle, Joanne T. Benson, Dirk R. Larson, Terry M. Therneau, Angela Dispenzieri, Shaji Kumar, L. Joseph Melton, S. Vincent Rajkumar |
Abstract |
The purpose of this study was to define the risk of progression and survival of patients with smoldering Waldenström macroglobulinemia (SWM). SWM is defined clinically as having a serum monoclonal IgM protein≥3 g/dL and/or≥10% bone marrow lymphoplasmacytic infiltration but no evidence of end-organ damage (anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly). We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of SWM between 1974 and 1995. During 285 cumulative person-years of follow-up of the 48 patients with SWM (median, 15.4 years), 34 (71%) progressed to symptomatic Waldenström macroglobulinemia (WM) requiring treatment, one to primary amyloidosis, and one to lymphoma (total, 75%). The cumulative probability of progression to symptomatic WM, amyloidosis, or lymphoma was 6% at 1 year, 39% at 3 years, 59% at 5 years, and 68% at 10 years. The major risk factors for progression were percentage of lymphoplasmacytic cells in the bone marrow, size of the serum M-spike, and the hemoglobin value. Patients with SWM should be followed and not treated until symptomatic WM develops. Treatment on a clinical trial for those at greatest risk of progression should be considered. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 5 | 45% |
Chile | 1 | 9% |
India | 1 | 9% |
Turkey | 1 | 9% |
Unknown | 3 | 27% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 64% |
Science communicators (journalists, bloggers, editors) | 2 | 18% |
Scientists | 1 | 9% |
Practitioners (doctors, other healthcare professionals) | 1 | 9% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Colombia | 2 | 2% |
Spain | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 83 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 14% |
Other | 11 | 13% |
Researcher | 10 | 11% |
Student > Master | 9 | 10% |
Student > Postgraduate | 8 | 9% |
Other | 18 | 21% |
Unknown | 19 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 50 | 57% |
Biochemistry, Genetics and Molecular Biology | 5 | 6% |
Agricultural and Biological Sciences | 4 | 5% |
Linguistics | 1 | 1% |
Immunology and Microbiology | 1 | 1% |
Other | 3 | 3% |
Unknown | 23 | 26% |